Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of FTY720 combined with tacrolimus and corticosteroids in patients receiving a kidney transplant

• Phase: Phase 3

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Fingolimod Hydrochloride

Criteria

Inclusion Criteria

• Completed the 12 month core study

• Informed consent Exclusion Criteria

• N/A Other protocol-defined exclusion criteria may apply.